BioCentury | Apr 15, 2013
Company News

Immtech International Inc. deal

...including Auburn University (Auburn, Ala.), Duke University (Durham, N.C.) and Georgia State Universities (Atlanta, Ga.). Immtech...
...in the company, and receive royalties based on sales and a percentage of milestones that Immtech...
...future licensing. The consortium will develop the compounds to the preclinical stage, at which point Immtech...
BioCentury | Apr 15, 2013
Company News

Immtech International Inc., Pharm-Eco Laboratories Inc. deal

...research consortium led by the University of North Carolina, Chapel Hill (See BioCentury, March 24). Immtech...
...transfer rights to commercialize the compounds from Pharm-Eco, which originally licensed them from the consortium. Immtech...
...oral form. Immtech expects the analogs to be orally available and less toxic than pentamidine. Immtech...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

...Phase III ACCLAIM study of immune modulation therapy for NYHA Class II heart failure 4/21/09 Immtech Pharmaceuticals Inc....
BioCentury | Apr 27, 2009
Company News

Immtech infectious news

...include SVP for pharmaceutical development and CMO Carol Olson, who will remain as a consultant. Immtech...
...disease compounds and has obtained letters of interest for its HCV discovery program. Last year, Immtech...
...PCP), and in Phase II testing to treat and prevent malaria. At Dec. 31, 2008, Immtech...
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...to treat HCV after an independent DMC raised safety concerns about the studies' higher dose Immtech...
BioCentury | Feb 25, 2008
Finance

Ebb & Flow

...end of October. Milnacipran is marketed as an antidepressant outside of the U.S. Clinical milestones Immtech...
BioCentury | Feb 25, 2008
Clinical News

Pafuramidine: Development discontinued

...all trials of pafuramidine after data revealed liver abnormalities in a South African safety study. Immtech...
...and pneumocystis carinii pneumonia (PCP), and in Phase II testing to treat and prevent malaria. Immtech Pharmaceuticals Inc....
BioCentury | Feb 23, 2008
Clinical News

Immtech ending pafuramidine development

...in a South African safety study ( See BioCentury Extra, Wednesday, Dec. 26, 2007 ). Immtech...
...trypanosomiasis) and pneumocystis carinii pneumonia (PCP), and Phase II testing to treat and prevent malaria. Immtech...
...will now focus on its preclinical compounds targeting HCV and drug-resistant bacterial and fungal infections. Immtech...
BioCentury | Jan 7, 2008
Finance

Ebb & Flow

...with FDA. The primary endpoint is now overall survival instead of 12-month survival (see B16). Immtech...
...and pneumocystis carinii pneumonia (PCP), and is in Phase II to treat and prevent malaria. Immtech...
BioCentury | Dec 27, 2007
Company News

Immtech's DB289 placed on hold

IMM fell $2.97 (51%) to $2.88 after FDA placed the company's pafuramidine (DB289) program on clinical hold. The decision was based on data from an ongoing South African safety study that IMM said showed "abnormal...
Items per page:
1 - 10 of 123
BioCentury | Apr 15, 2013
Company News

Immtech International Inc. deal

...including Auburn University (Auburn, Ala.), Duke University (Durham, N.C.) and Georgia State Universities (Atlanta, Ga.). Immtech...
...in the company, and receive royalties based on sales and a percentage of milestones that Immtech...
...future licensing. The consortium will develop the compounds to the preclinical stage, at which point Immtech...
BioCentury | Apr 15, 2013
Company News

Immtech International Inc., Pharm-Eco Laboratories Inc. deal

...research consortium led by the University of North Carolina, Chapel Hill (See BioCentury, March 24). Immtech...
...transfer rights to commercialize the compounds from Pharm-Eco, which originally licensed them from the consortium. Immtech...
...oral form. Immtech expects the analogs to be orally available and less toxic than pentamidine. Immtech...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

...Phase III ACCLAIM study of immune modulation therapy for NYHA Class II heart failure 4/21/09 Immtech Pharmaceuticals Inc....
BioCentury | Apr 27, 2009
Company News

Immtech infectious news

...include SVP for pharmaceutical development and CMO Carol Olson, who will remain as a consultant. Immtech...
...disease compounds and has obtained letters of interest for its HCV discovery program. Last year, Immtech...
...PCP), and in Phase II testing to treat and prevent malaria. At Dec. 31, 2008, Immtech...
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...to treat HCV after an independent DMC raised safety concerns about the studies' higher dose Immtech...
BioCentury | Feb 25, 2008
Finance

Ebb & Flow

...end of October. Milnacipran is marketed as an antidepressant outside of the U.S. Clinical milestones Immtech...
BioCentury | Feb 25, 2008
Clinical News

Pafuramidine: Development discontinued

...all trials of pafuramidine after data revealed liver abnormalities in a South African safety study. Immtech...
...and pneumocystis carinii pneumonia (PCP), and in Phase II testing to treat and prevent malaria. Immtech Pharmaceuticals Inc....
BioCentury | Feb 23, 2008
Clinical News

Immtech ending pafuramidine development

...in a South African safety study ( See BioCentury Extra, Wednesday, Dec. 26, 2007 ). Immtech...
...trypanosomiasis) and pneumocystis carinii pneumonia (PCP), and Phase II testing to treat and prevent malaria. Immtech...
...will now focus on its preclinical compounds targeting HCV and drug-resistant bacterial and fungal infections. Immtech...
BioCentury | Jan 7, 2008
Finance

Ebb & Flow

...with FDA. The primary endpoint is now overall survival instead of 12-month survival (see B16). Immtech...
...and pneumocystis carinii pneumonia (PCP), and is in Phase II to treat and prevent malaria. Immtech...
BioCentury | Dec 27, 2007
Company News

Immtech's DB289 placed on hold

IMM fell $2.97 (51%) to $2.88 after FDA placed the company's pafuramidine (DB289) program on clinical hold. The decision was based on data from an ongoing South African safety study that IMM said showed "abnormal...
Items per page:
1 - 10 of 123